Cargando…

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

BACKGROUND: Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19. METHODS: In an open-label, adaptive, multi...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362592/ https://www.ncbi.nlm.nih.gov/pubmed/34351722 http://dx.doi.org/10.1056/NEJMoa2103417

Ejemplares similares

CRITICALLY ILL COVID-19 PATIENTS AND THERAPEUTIC ANTICOAGULATION WITH HEPARIN
por: Vu, Michael, et al.
Publicado: (2022)

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Publicado: (2021)

Continuation of therapeutic dose heparin for critically ill patients with COVID-19
por: Bradbury, Charlotte A., et al.
Publicado: (2023)

Regional Anticoagulation with Citrate is Superior to Systemic Anticoagulation with Heparin in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
por: Park, Joon-Sung, et al.
Publicado: (2011)

Bivalirudin or heparin: which anticoagulation strategy for critically ill cardiac surgery patients?
por: Pappalardo, F, et al.
Publicado: (2014)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection
por: McGlynn, Fergal, et al.
Publicado: (2020)

Mortality, critical illness, and mechanical ventilation among hospitalized patients with COVID-19 on therapeutic anticoagulants
por: Patel, Niti G., et al.
Publicado: (2021)

Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials
por: Bonfim, Luana C.M.G., et al.
Publicado: (2023)

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients
por: Gabara, C., et al.
Publicado: (2023)

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients
por: Gabara, C., et al.
Publicado: (2023)

ANTICOAGULATION, BLEEDING, AND IMMUNOTHROMBOSIS IN CRITICALLY ILL PATIENTS WITH COVID-19
por: PAEZ VARGAS, JUAN, et al.
Publicado: (2021)

Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19
por: Hoogenboom, Wouter S., et al.
Publicado: (2022)

The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies
por: Pilia, Eros, et al.
Publicado: (2023)

Clinical Outcomes in Critically-Ill Patients with COVID-19 Treated with Therapeutic Dose of Anticoagulants for Suspected Thromboembolism
por: Naing, Phyu Thin, et al.
Publicado: (2021)

The haemostatic profile in critically ill COVID-19 patients receiving therapeutic anticoagulant therapy: An observational study
por: Tsantes, Argirios E., et al.
Publicado: (2020)

Fatal iliopsoas and rectus sheath hemorrhage in a critically ill patient with COVID-19 on therapeutic anticoagulation
por: Ryalino, Christopher, et al.
Publicado: (2022)

Non-anticoagulant heparin derivatives for COVID-19 treatment
por: Cao, Min, et al.
Publicado: (2023)

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials
por: Pilia, Eros, et al.
Publicado: (2022)

Albumin Infusion in Critically Ill COVID-19 Patients: Hemodilution and Anticoagulation
por: Ramadori, Giuliano
Publicado: (2021)

Aggressive Anticoagulation May Decrease Mortality in Obese Critically Ill COVID-19 Patients
por: Drakos, Panagiotis, et al.
Publicado: (2021)

Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin
por: Ting, Clara, et al.
Publicado: (2018)

Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients
por: Stattin, K., et al.
Publicado: (2020)

Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease
por: Wenzler, Eric, et al.
Publicado: (2020)

Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia
por: Tacquard, Charles, et al.
Publicado: (2021)

COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
por: Jimenez, David, et al.
Publicado: (2022)

Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database
por: Zou, Zhi-ye, et al.
Publicado: (2022)

Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study
por: Ferrandis, R., et al.
Publicado: (2023)

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
por: Buijsers, Baranca, et al.
Publicado: (2020)

COVID-19 in the Critically Ill: Too Risky for High-Dose Anticoagulation?
por: Paez Vargas, Juan José, et al.
Publicado: (2021)

Heparin anticoagulation versus regional citrate anticoagulation for membrane therapeutic plasma exchange in patients with increased bleeding risk
por: Jiao, Jing, et al.
Publicado: (2023)

Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials
por: Ena, Javier, et al.
Publicado: (2022)

Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis
por: Hasan, Syed Shahzad, et al.
Publicado: (2020)

POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes
por: Tritschler, Tobias, et al.
Publicado: (2022)

Heparin or nonheparin anticoagulants for VITT
por: Arnold, Donald M.
Publicado: (2022)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19
por: Braz-de-Melo, Heloísa Antoniella, et al.
Publicado: (2021)

The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review
por: Gozzo, Lucia, et al.
Publicado: (2020)

Non-Anticoagulant Heparins as Heparanase Inhibitors
por: Cassinelli, Giuseppe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ujmjck15pqrl5737a9k71rgoq